The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Netherlands === A ban on beak trimming in the Netherlands was first announced in 1996, but due to objections from the poultry sector it was delayed for years. In June 2013, the government struck an agreement between poultry farmers and animal welfare groups to phase out debeaking and prohibit it in 2018. The prohibition on trimming eventually went into effect on 1 January 2019.
=== Interactions === Upwards of 12 interacting proteins have been predicted for C3orf62. Interacting proteins with the strongest confidence to interact with C3orf62 include: HAUS augmin-like complex subunit 1 (HAUS-1), Inhibitor of growth protein 5 (ING5), Thioredoxin domain-containing protein 9 (TXNDC9), and MORF4-family associated proteins (MORF4L1, MFRAP1). Chemicals known to interact with C3orf62 include the following: Aflatoxin B1, Hydralazine, Valproic acid, and Decitabine.
Paulovich is a Professor in Clinical Research, an Aven Foundation Endowed Chair, and the Director of Early Detection Initiative at the Fred Hutchinson Cancer Research Center. She was inducted to the American Society for Clinical Inviestigation in 2012. Paulovich is an expert in proteomics. Her targeted proteomics method uses multiple reaction monitoring mass spectrometry to target cancer biomarkers with ongoing clinical trials, and was named Method of the Year in 2012 by Nature Methods. She founded Precision Assays in 2016, whose rights to targeted assays were acquired by CellCarta in 2022. 2014 Life Science Innovation Northwest Woman to Watch in Life Science Award 2015 Human Proteome Organization (HUPO) Distinguished Achievement in Proteomic Sciences Award Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample (2011) US 20130052668 A1 Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample (2011) US 20130052669 A1
Sources: en.wikipedia.org
== Campaign == The campaign for was unusually short, lasting only seven weeks after the vote was brought forward from May to 18 March following negotiations between the Round Table and the government of Hans Modrow on 28 January. This tight schedule posed significant organizational challenges. Only the PDS, as the successor to the SED, possessed the necessary infrastructure and financial resources for a full campaign. In contrast, newly formed opposition parties and civil rights groups were still defining their platforms and had minimal experience in electioneering. Their shortcomings were partially mitigated by substantial support from West German parties, which provided logistical and strategic assistance to their Eastern counterparts. Western support facilitated the creation of several electoral alliances. The CDU partnered with the German Social Union and Democratic Awakening to form the Alliance for Germany. The FDP backed the Association of Free Democrats, which included the Liberal Democratic Party of Germany (LDPD) and the minor FDP of the GDR. These alliances were established only weeks before the election, relying heavily on Western assistance such as the CDU's "district partnerships" and the participation of West German campaigners. At the outset, the SPD appeared likely to win, benefiting from historical roots in the region and strong backing from the West German SPD. Early polls showed it leading with 54 percent support, ahead of the PDS and CDU. Despite early advantages, the SPD's momentum declined as reunification became the dominant issue.
=== Helmholtz === The model dubbed the 'electric double layer' was first introduced by Hermann von Helmholtz. It assumes that a solution is only composed of electrolytes, no reactions occur near the electrode which could transfer electrons, and that the only Van der Waals interactions are present between the ions in solution and the electrode. These interactions arise only due to the charge density associated with the electrode which arises from either an excess or deficiency of electrons at the electrode's surface. To maintain electrical neutrality the charge of the electrode will be balanced by a redistribution of ions close to its surface. The attracted ions thus form a layer balancing the electrode's charge. The closest distance an ion can come to the electrode will be limited to the radius of the ion plus a single solvation sphere around an individual ion. Overall, two layers of charge and a potential drop from the electrode to the edge of the outer layer (outer Helmholtz Plane) are observed. Given the above description, the Helmholtz model is equivalent in nature to an electrical capacitor with two separated plates of charge, for which a linear potential drop is observed at increasing distance from the plates. The Helmholtz model, while a good foundation for the description of the interface does not take into account several important factors: diffusion/mixing in solution, the possibility of adsorption on to the surface and the interaction between solvent dipole moments and the electrode.
=== Conformation change mechanism pathway (without proteolysis) === αVβ6 integrin was the first integrin to be identified as TGF-β1 activator. LAPs contain an RGD motif which is recognized by vast majority of αV containing integrins, and αVβ6 integrin can activate TGF-β1 by binding to the RGD motif present in LAP-β1 and LAP-β3. Upon binding, it induces adhesion-mediated cell forces that are translated into biochemical signals which can lead to liberation/activation of TGFb from its latent complex. This pathway has been demonstrated for activation of TGF-β in epithelial cells and does not associate MMPs.
Sources: en.wikipedia.org
== Diagnosis == Screening for muscle atrophy is limited by a lack of established diagnostic criteria, although many have been proposed. Diagnostic criteria for other conditions such as sarcopenia or cachexia can be used. These syndromes can also be identified with screening questionnaires. Muscle mass and changes can be quantified on imaging studies such as CT scans or Magnetic resonance imaging (MRI). Biomarkers such as urine urea can be used to roughly estimate muscle loss during circumstances of rapid muscle loss. Other biomarkers are currently under investigation but are not used in clinical practice.
1993/3045) Broadcasting (Prescribed Countries) (Amendment) Order 1993 (S.I. 1993/3046) Broadcasting (Foreign Satellite Programmes) (Specified Countries) (Amendment) Order 1993 (S.I. 1993/3047) Road Vehicles (Construction and Use) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3048) Public Lending Right Scheme 1982 (Commencement of Variation) Order 1993 (S.I. 1993/3049) Notification of New Substances Regulations 1993 (S.I. 1993/3050) Hearing Aid Council Monetary Penalty (Increase) Order 1993 (S.I. 1993/3052) Commercial Agents (Council Directive) Regulations 1993 (S.I. 1993/3053) Local Authorities (Capital Finance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/3054) Income Tax (Interest Relief) (Qualifying Lenders) (No. 4) Order 1993 (S.I. 1993/3055) Education (University Commissioners) Order 1993 (S.I. 1993/3056) National Health Service Trusts (Consultation on Dissolution) (Scotland) Regulations 1993 (S.I. 1993/3057) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation No.2) Order 1993 (S.I. 1993/3058) Non-Domestic Rating Contributions (Scotland) Amendment Regulations 1993 (S.I. 1993/3059) New Town (Livingston) Winding Up Order 1993 (S.I. 1993/3060) New Town (Irvine) Winding Up Order 1993 (S.I. 1993/3061) New Town (Cumbernauld) Winding Up Order 1993 (S.I. 1993/3062) Herring (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3063) Passenger and Goods Vehicles (Recording Equipment) (Approval of Fitters and Workshops) (Fees) (Amendment) Regulations 1993 (S.I.
Mid-Atlantic Ridge province, East Scotia Ridge province, northern East Pacific Rise province, central East Pacific Rise province, southern East Pacific Rise province, south of the Easter Microplate, Indian Ocean province, four provinces in the western Pacific and many more.
=== Russell indices in Japan === Russell/Nomura equity indices for Japan (calculated with Nomura Securities Co., Ltd.) offer free-float adjusted broad market or style benchmarks for investors in that country.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.